SG10201900072VA - A pharmaceutical combination and method for regulation of tumor microenvironment and immunotherapy - Google Patents
A pharmaceutical combination and method for regulation of tumor microenvironment and immunotherapyInfo
- Publication number
- SG10201900072VA SG10201900072VA SG10201900072VA SG10201900072VA SG10201900072VA SG 10201900072V A SG10201900072V A SG 10201900072VA SG 10201900072V A SG10201900072V A SG 10201900072VA SG 10201900072V A SG10201900072V A SG 10201900072VA SG 10201900072V A SG10201900072V A SG 10201900072VA
- Authority
- SG
- Singapore
- Prior art keywords
- tumor microenvironment
- immunotherapy
- regulation
- pharmaceutical combination
- combination
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 230000033228 biological regulation Effects 0.000 title abstract 2
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 abstract 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 abstract 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 abstract 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 abstract 1
- 230000008629 immune suppression Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 abstract 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862614306P | 2018-01-05 | 2018-01-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201900072VA true SG10201900072VA (en) | 2019-08-27 |
Family
ID=65003253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201900072VA SG10201900072VA (en) | 2018-01-05 | 2019-01-03 | A pharmaceutical combination and method for regulation of tumor microenvironment and immunotherapy |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11840570B2 (pt) |
| EP (1) | EP3508224A1 (pt) |
| JP (1) | JP7084035B2 (pt) |
| KR (1) | KR102338992B1 (pt) |
| CN (1) | CN110013556B (pt) |
| AR (1) | AR114507A1 (pt) |
| AU (1) | AU2019200033B2 (pt) |
| BR (1) | BR102019000155A2 (pt) |
| CA (1) | CA3028895C (pt) |
| IL (1) | IL264068B2 (pt) |
| MX (1) | MX2019000286A (pt) |
| NZ (1) | NZ749727A (pt) |
| RU (1) | RU2738566C2 (pt) |
| SG (1) | SG10201900072VA (pt) |
| TR (1) | TR201900059A2 (pt) |
| TW (1) | TWI739053B (pt) |
| ZA (1) | ZA201900048B (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI741731B (zh) * | 2019-08-15 | 2021-10-01 | 大陸商深圳微芯生物科技股份有限公司 | 一種含西達本胺的抗腫瘤藥物組合物及其應用 |
| KR20210028339A (ko) * | 2019-09-04 | 2021-03-12 | 크리스탈지노믹스(주) | Hdac 저해제와 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 약학 조성물 |
| US11878009B2 (en) | 2019-09-10 | 2024-01-23 | Great Novel Therapeutics Biotech & Medicals Corporation | Anticancer combination of chidamide and celecoxib salts |
| EP4028002A4 (en) * | 2019-09-11 | 2023-06-14 | GNT Biotech & Medicals Corporation | ANTI-CANCER COMBINATION OF CHIDAMID AND CELECOXIB |
| US20230073803A1 (en) * | 2019-12-16 | 2023-03-09 | Themis Medicare Limited | Pharmaceutical composition of cyclooxygenase - 2 inhibitors |
| IL297687A (en) * | 2020-04-30 | 2022-12-01 | Great Novel Therapeutics Biotech & Medicals Corp | Histone deacetylase inhibitors for immune modulation in the tumor microenvironment |
| WO2022046792A2 (en) * | 2020-08-25 | 2022-03-03 | Huyabio International, Llc | Methods and compositions for genetic modulation of tumor microenvironments |
| WO2023280175A1 (en) * | 2021-07-06 | 2023-01-12 | National Institute Of Biological Sciences, Beijing | Methods for treating complex i deficiencies or cancers by modulating gro3p biosynthesis |
| CN114146181B (zh) * | 2021-10-29 | 2022-09-09 | 徐诺药业(南京)有限公司 | 含Pan-HDAC和免疫检查点抑制剂的组合及应用 |
| CN116236468A (zh) * | 2021-12-07 | 2023-06-09 | 深圳先进技术研究院 | 二甲双胍在制备增强免疫检查点抑制剂效果的抗肿瘤药物中的应用 |
| WO2023193705A1 (zh) * | 2022-04-07 | 2023-10-12 | 深圳微芯生物科技股份有限公司 | 西奥罗尼在抗胰腺癌中的用途 |
| CN115501226B (zh) * | 2022-09-29 | 2024-02-23 | 成都以邦医药科技有限公司 | 一种化合物在制备促进t细胞浸润的药物中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1743654A1 (en) | 2005-07-15 | 2007-01-17 | TopoTarget Germany AG | Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases |
| MX365393B (es) | 2011-09-13 | 2019-05-31 | Pharmacyclics Llc | Formulaciones de inhibidor de histona deacetilasa en combinación con bendamustina y usos de las mismas. |
| EP3030322A2 (en) | 2013-08-05 | 2016-06-15 | Cambridge Enterprise Limited | Inhibition of cxcr4 signaling in cancer immunotherapy |
| WO2016026854A2 (en) | 2014-08-18 | 2016-02-25 | Apceth Gmbh & Co. Kg | Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells |
| EP3192517A4 (en) * | 2014-08-19 | 2018-04-25 | National University Corporation Okayama University | Method for enhancing immune cell function and method for assessing immune cell multifunctionality |
| WO2016109668A1 (en) * | 2014-12-31 | 2016-07-07 | Anthrogenesis Corporation | Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells |
| WO2017035453A1 (en) | 2015-08-26 | 2017-03-02 | The Johns Hopkins University | Compositions and methods for treating solid tumors |
| US20180244783A1 (en) | 2015-08-31 | 2018-08-30 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| US20170196835A1 (en) | 2016-01-08 | 2017-07-13 | Euclises Pharmaceuticals, Inc. | Combination of a chromene compound and a second active agent |
| MX2018009247A (es) * | 2016-01-28 | 2019-03-11 | Univ Indiana Res & Tech Corp | Uso de inhibidores de histona deacetilasa para aumentar las inmunoterapias. |
| JP6860922B2 (ja) | 2016-02-12 | 2021-04-21 | 国立大学法人 岡山大学 | 免疫機能の検査方法、がん患者の選別方法、がんの治療効果予測方法、細胞内カルシウムイオン濃度上昇剤、腫瘍組織におけるエフェクター・メモリー（ＥＭ）とエフェクター（ｅｆｆ）の選択的機能向上剤、がん治療薬の効果のモニタリング方法 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| US11878009B2 (en) * | 2019-09-10 | 2024-01-23 | Great Novel Therapeutics Biotech & Medicals Corporation | Anticancer combination of chidamide and celecoxib salts |
-
2019
- 2019-01-03 KR KR1020190000807A patent/KR102338992B1/ko active IP Right Grant
- 2019-01-03 AU AU2019200033A patent/AU2019200033B2/en active Active
- 2019-01-03 SG SG10201900072VA patent/SG10201900072VA/en unknown
- 2019-01-03 TR TR2019/00059A patent/TR201900059A2/tr unknown
- 2019-01-03 IL IL264068A patent/IL264068B2/en unknown
- 2019-01-03 NZ NZ749727A patent/NZ749727A/en unknown
- 2019-01-04 US US16/240,081 patent/US11840570B2/en active Active
- 2019-01-04 TW TW108100337A patent/TWI739053B/zh active
- 2019-01-04 CN CN201910008912.6A patent/CN110013556B/zh active Active
- 2019-01-04 ZA ZA201900048A patent/ZA201900048B/en unknown
- 2019-01-04 AR ARP190100021A patent/AR114507A1/es unknown
- 2019-01-04 JP JP2019000290A patent/JP7084035B2/ja active Active
- 2019-01-04 BR BR102019000155-0A patent/BR102019000155A2/pt not_active Application Discontinuation
- 2019-01-04 CA CA3028895A patent/CA3028895C/en active Active
- 2019-01-04 EP EP19150392.9A patent/EP3508224A1/en active Pending
- 2019-01-07 MX MX2019000286A patent/MX2019000286A/es unknown
- 2019-01-09 RU RU2019100078A patent/RU2738566C2/ru active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3028895C (en) | 2023-10-17 |
| AR114507A1 (es) | 2020-09-16 |
| CN110013556B (zh) | 2024-08-23 |
| NZ749727A (en) | 2020-07-31 |
| EP3508224A1 (en) | 2019-07-10 |
| MX2019000286A (es) | 2019-07-08 |
| US11840570B2 (en) | 2023-12-12 |
| IL264068A (en) | 2019-05-30 |
| ZA201900048B (en) | 2019-10-30 |
| KR20190083990A (ko) | 2019-07-15 |
| RU2738566C2 (ru) | 2020-12-14 |
| JP2019142841A (ja) | 2019-08-29 |
| AU2019200033B2 (en) | 2020-09-10 |
| TW201934143A (zh) | 2019-09-01 |
| US20190211103A1 (en) | 2019-07-11 |
| CA3028895A1 (en) | 2019-07-05 |
| IL264068B2 (en) | 2023-07-01 |
| RU2019100078A3 (pt) | 2020-07-09 |
| RU2019100078A (ru) | 2020-07-09 |
| IL264068B1 (en) | 2023-03-01 |
| TWI739053B (zh) | 2021-09-11 |
| BR102019000155A2 (pt) | 2019-08-20 |
| TR201900059A2 (tr) | 2019-07-22 |
| KR102338992B1 (ko) | 2021-12-14 |
| AU2019200033A1 (en) | 2019-07-25 |
| JP7084035B2 (ja) | 2022-06-14 |
| CN110013556A (zh) | 2019-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201900072VA (en) | A pharmaceutical combination and method for regulation of tumor microenvironment and immunotherapy | |
| MX2020005701A (es) | Células efectoras inmunitarias potenciadas y usos de las mismas. | |
| WO2017059319A3 (en) | Combination therapy of bromodomain inhibitors and checkpoint blockade | |
| PH12019501414A1 (en) | Amino acid compositions and methods for the treatment of liver diseases | |
| SG10201900886RA (en) | Methods and therapeutic combinations for treating tumors | |
| PH12020550936A1 (en) | Combination drug including tlr7 agonist | |
| MX2017003227A (es) | Terapias de combinacion de inhibidores de alk. | |
| MX2022008868A (es) | Tratamiento del cancer con tg02. | |
| MX2018015352A (es) | Subtipos de receptores y compuestos retinoides y rexinoides de funcion selectiva combinados con moduladores inmunitarios para inmunoterapia contra el cancer. | |
| WO2019006005A3 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA | |
| MX2021006734A (es) | Metodo para tratar el cancer. | |
| MY185579A (en) | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment | |
| MX2018002344A (es) | Metodo para tratar el cancer. | |
| MX2017007256A (es) | Inhibidor de bromodominio como adyuvante en la inmunoterapia contra el cancer. | |
| MX2020000467A (es) | Compuestos retinoides y rexinoides inmunomoduladores en combinacion con inmunomoduladores para inmunoterapia contra cancer. | |
| PH12021551036A1 (en) | Anti-liv1 immune cell cancer therapy | |
| SG11202113365SA (en) | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer | |
| MX2021013354A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
| EP4253419A3 (en) | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer | |
| EP3991749A3 (en) | A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody | |
| EP4371584A3 (en) | Scaffolds to treat solid tumor cells and escape variants | |
| EP4342544A3 (en) | Enhancing the therapeutic activity of an immune checkpoint inhibitor | |
| EP4324477A3 (en) | Oxabicycloheptanes for modulation of immune response | |
| EP3463398A4 (en) | IMMUNITY CHECKPOINT INHIBITORS AND CYTOTOXIC T CELLS FOR TREATING CANCER | |
| MX2020009478A (es) | Compuestos y sus usos para tratar tumores en un paciente. |